Concept↦Documents↦Required Documents↦Investigator's Brochure
What is it? Why is it important?
The Investigator’s Brochure (IB) is a critically important document in drug development. It provides for any drug (IMP) under investigation a comprehensive summary of currently available results obtained from:
- Pre-clinical studies (e.g. in vitro analysis, animal experiments)
- Drug (IMP) studies in humans (e.g. clinical studies)
The IB summarises clinical (and non-clinical) data, such as:
- Drug dosing results, including dosing frequency and intervals
- Method(s) of administration
- Safety information (e.g. based on the ongoing monitoring and occurrence of AEs and ADRs), including applicable treatments
- Preventative measures and precautionary procedures, which provide insight to the clinical management of study participants
- Additional warning signs
The IB is continuously updated as new information becomes available during study conduct. This allows for ongoing adaptations of the IB in order to ensure participant safety and rights remain protected.
More
The IB provides important background information on the study drugs (IMP). As a result the IB can be used to plan for:
- Expected safety concerns (e.g. AEs, ADR, safety risks)
- A risk/benefit assessment of the planned treatment
- The optimal method of administration (e.g. oral, injection, suppository)
- The optimal drug dosing (e.g. drug escalation and tolerance levels, frequency of dosing intervals)
What do I need to do?
As a SP-INV you are responsible to:
- Maintain ongoing full insight regarding the drug under investigation
- Follow any relevant IB updates and consider potential safety adaptations during study conduct (e.g. reassessment of the study risk-benefit ratio)
- Provide participating Site-INV(s) with IB information
As a Site-INV:
- Read the chapter “Summary of data and guidance for the Investigator”
- Based on this information, acquire current knowledge regarding drug safety risks and side effects, including the implementation of local preventative measures
The IB provides the SP-INV/Site-INV and other study involved staff with:
- Information that facilitates their understanding with respect to the study rationale, including the required compliance with many key features of the study protocol
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
External Links
Swissmedic – see in particular
- AW Working Instruction to “Clinical Trial Application Dossier” Section 6
References
ICH GCP E6(R2) – see in particular guideline
- 7 Investigator’s Brochure